Return to program book search

Session Information

SYM S013 - Common Controversies in Dermatologic Drug Therapy

Open admission to eligible categories, no tuition or ticket

Subject:

Date: Saturday, August 03

CME Credits: 3.00

Location: Grand Ballroom West

Time: 2:00 PM - 5:00 PM

Director: Stephen E. Wolverton, MD, FAAD

Speakers:

  • James Q. Del Rosso, DO - Handout
  • Theodore Rosen, MD, FAAD
  • Courtney Reynolds Schadt, MD, FAAD
  • Mary M. Tomayko, MD, PhD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Utilize the basic principles in studying and making rational conclusions when confronted with various controversies in dermatologic drug therapy.
  • Utilize effectively the relatively limited number of statistical tests to evaluate these controversies.
  • Assess the safety and efficacy of therapies such as rituximab, TNF inhibitors, systemic antibacterial agents, and a number of other drug therapies.

Description:
There are numerous controversies and difficult questions surrounding many aspects of dermatologic drug therapy. This three-hour session will directly and decisively address a variety of controversies of management for the spectrum of biologic therapies and traditional systemic drug therapies with a definite element of risk. Risk management strategies will be emphasized, particularly regarding topics in which there has been significant medicolegal experience (such as isotretinoin and IBD). Additional topics include discussions on antimicrobial resistance, safety of long-term management of inflammatory dermatoses, and the pros and cons for considering rituximab the drug of choice for pemphigus vulgaris.

References:

  • Wolverton SE. Comprehensive dermatologic drug therapy. 3rd ed. Elsevier, London, 2012.

Schedule:

Saturday, August 03
2:00 PMIntroduction – principles to address medical controversies / Dr. Wolverton
2:10 PMLong-term management of common inflammatory dermatoses: Does it help? Is it safe? / Dr. Del Rosso
2:45 PMPros and cons for rituximab being the drug of choice for pemphigus vulgaris / Dr. Tomayko
3:20 PMBiologics versus traditional systemic therapies for pyoderma gangrenosum / Dr. Schadt
3:55 PMAntimicrobial resistance update / Dr. Rosen
4:30 PMCurrent medicolegal controversies involving dermatologic drugs: an easy statistical solution / Dr. Wolverton